4.4 Review

Is there a role for immunotherapy in malignant pleural mesothelioma?

Journal

MEDICAL ONCOLOGY
Volume 35, Issue 7, Pages -

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12032-018-1156-x

Keywords

Malignant pleural mesothelioma; Immunotherapy; Immune checkpoint inhibitors; CAR T cell therapy

Categories

Ask authors/readers for more resources

Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available